Bukwang Pharm, Up 17.88% Amid COVID-19 (Dexamethasone) Theme Surge

On the 14th, the COVID-19 (Dexamethasone) theme rose by 3.14% compared to the previous day, showing strength, while Bukwang Pharmaceutical, which is attracting attention as a related stock, surged by 17.88% compared to the previous day. Bukwang Pharmaceutical is known as a manufacturer of pharmaceuticals and quasi-drugs (such as toothpaste).

[Graph] Major stock price changes in the COVID-19 (Dexamethasone) theme

According to provisional data compiled at 11:31, Bukwang Pharmaceutical is experiencing large net purchases by institutions, with institutions buying 100,000 shares.

[Table] Net trading volume of foreigners and institutions (unit: 10,000 shares)

According to the analysis by Thinkpool Robo Algorithm RASSI, Bukwang Pharmaceutical’s quant financial score is 18.27 points, ranking 11th in the quant financial ranking within the COVID-19 (Dexamethasone) related theme. This can be interpreted as Bukwang Pharmaceutical having relatively low investment attractiveness from a financial perspective. On the other hand, Hwanin Pharm ranked first in the quant financial ranking with higher growth, stability, and profitability scores compared to the average of other stocks.

[Table] Top stocks by financial score within the theme

※ The quant financial score is the result of the Robo Algorithm analyzing each company’s sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real-time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.